Results 201 to 210 of about 27,323 (260)
Cytomegalovirus Infection After Chimeric Antigen Receptor T-Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. [PDF]
Transpl Infect DisHan J +5 more
europepmc +1 more source
EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy. [PDF]
Cancer SciGao J +9 more
europepmc +1 more source
American Journal of Hematology, Volume 101, Issue 8, Page 2081-2085, August 2026.
Astrid Hundebøll Torpe +14 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Engineering bispecific antibodies
Current Opinion in Biotechnology, 1993Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire +2 more sources
Bispecific Antibodies in Lymphoma
International Reviews of Immunology, 1993info:eu-repo/semantics ...
Brissinck, J +4 more
openaire +3 more sources
Bispecific Antibodies for the Treatment of Neuroblastoma
SSRN Electronic Journal, 2022Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton +1 more
openaire +2 more sources
Production of Bispecific Antibodies
Current Protocols in Immunology, 1995AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire +2 more sources
A revival of bispecific antibodies
Trends in Biotechnology, 2004Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer +2 more
openaire +2 more sources
Bispecific antibodies in oncology
Nature Reviews Drug Discovery, 2022Arman, Esfandiari +2 more
openaire +2 more sources